Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
about
Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationHematopoietic stem and progenitor cell harvesting: technical advances and clinical utilityNew insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alonePreemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.Novel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.Advances in stem cell mobilization.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies.How do we mobilize and collect autologous peripheral blood stem cells?New strategies for stem cell mobilization.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.Plerixafor to the rescue: boosting peripheral blood stem cell mobilization in patients previously treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine (Hyper-CVAD) chemotherapy.Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration.
P2860
Q26825518-54496DA7-3714-4E10-BD25-8A02BD812E59Q27012881-D32085B3-55D7-40D9-98E1-3BF7935D3EEBQ34114055-720ACB91-F82A-4FB8-BD3B-118A777A8E6FQ34265754-2C6A80E0-84BB-4661-9CE3-0FDAC0C0EFC4Q35965373-4FE6AE3D-9196-4620-80DC-0F8940D61224Q36428104-D6D3CF8F-AA65-4B1D-97F1-C3BA4BD26A7DQ36569033-64A4A832-23AD-46B1-9918-6F737541E588Q37230855-0FE7B452-D397-469E-9CE6-54BC94DCCB09Q37424430-55237BB9-97E5-4DB0-9628-3B880CAA20BEQ37909447-1C821FC7-A5A0-41C7-ADD4-64B8F5E757F2Q37921284-0529CBE6-542F-4CCF-B619-0838AAC3C82DQ37923309-DBF5699E-5077-41DF-A531-B5A009F98436Q37943423-F2F620C2-BAFE-4F86-8D41-C84D16F63BE2Q38160461-2DA7301C-FCD2-4E49-B26C-40ED41113E00Q38176669-94750DC5-DC84-44B6-B6A4-5E3DBBF4E0F6Q38183225-013D3AAB-5092-44DE-9C87-E919F0CAC6C6Q38199707-1D579925-6ED1-4718-A1FD-AE76758AF761Q38200909-800DE075-53C6-42B1-B76D-5507464A6A18Q38256923-FCC58B60-1096-491F-B777-05EC72586DFDQ38978669-A08E5B7D-682E-4489-94A4-C74470266344Q41104670-5382AB59-78D8-4500-8979-6CC9CBCC79FFQ41267193-36A31678-17B5-47B1-9569-5FC3372FD526Q41274044-54AA1308-41C0-4E27-9F2E-9263C535B519Q41694417-9C3CCB05-D35A-4E94-BD84-80E74B89740EQ43563982-87031AD6-64CC-4441-9B63-33F6FED9572AQ44256421-81CF18B8-4A77-4285-A408-889BAF5D728DQ44607102-67124F6C-1C74-42CB-85CF-4A96F28AE422Q44923993-8F92FF0D-6693-40E9-82C9-EE41BA1BDF1EQ44986060-382B4AA2-A5E8-4F05-A4B6-95252A5F4D09Q45513822-A368DCFF-59C9-4103-9571-0253CFBCD671Q45735258-987B89E4-216B-460B-A129-73BDB1161916Q46089696-FAE2D292-E67D-4F77-A573-982C6BFF1BC0Q46877033-8EF8A2B9-5198-460A-BFC7-7BBC3249DB62Q47581276-268C25EE-3204-4547-8A23-443715900017Q47914097-6E8DCAC7-80EA-4A00-AE3E-F50CE22E84B7Q48251584-4B549559-2F68-4163-B7E7-02108EB433EDQ48251589-9D1FCBD7-20D5-4E13-9A6B-C6412B4714F7Q50092819-CFBA15CC-6B9B-4448-BA1E-CDB63C1D18FDQ50690379-DCDA6C80-2BF3-4B69-99AA-98930968A298Q50942920-175BAC90-DD49-49D7-9252-B731D94A8D1C
P2860
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Development and validation of ...... oietic stem cell mobilization.
@en
Development and validation of ...... oietic stem cell mobilization.
@nl
type
label
Development and validation of ...... oietic stem cell mobilization.
@en
Development and validation of ...... oietic stem cell mobilization.
@nl
prefLabel
Development and validation of ...... oietic stem cell mobilization.
@en
Development and validation of ...... oietic stem cell mobilization.
@nl
P2093
P2860
P356
P1476
Development and validation of ...... oietic stem cell mobilization.
@en
P2093
P2860
P2888
P356
10.1038/BMT.2010.78
P407
P577
2010-04-12T00:00:00Z
P5875
P6179
1036099459